STAR IMAGING & PATH LAB IPO
A Glimpse into the IPO
| IPO Period | 08th – 12th Aug 2025 |
|---|---|
| Listing on | 18 Aug 2025 |
| Price Band | ₹135 – ₹142 |
| Lot Size & Minimum Investment | 1000 shares – ₹142,000 |
| Total Issue Size | ₹69.47 crores |
Star Imaging & Path Lab Limited is set to open its Initial Public Offering (IPO) on August 8, 2025, offering investors an opportunity to participate in a prominent healthcare diagnostics company. This IPO aims to raise capital through a combination of a fresh issue of shares and an offer for sale by existing shareholders.
Important Dates for Investors
- Opening Date: 08 Aug 2025
- Closing Date: 12 Aug 2025
- UPI Payment Deadline: 12 Aug 2025 (5 PM)
- Allotment Announcement: 13 Aug 2025
- Refund Processing: 14 Aug 2025
- Demat Credit: 14 Aug 2025
- Stock Market Listing: 18 Aug 2025
- Mandate Validity End: 28 Aug 2025
- Anchor Investor Lock-in Release (50%): 12 Sep 2025
- Anchor Investor Lock-in Release (Remaining): 11 Nov 2025
*Dates may be revised as per official updates. Investors are advised to refer to official announcements for any changes.
About the Company: Star Imaging & Path Lab
Founded in 2004, Star Imaging and Path Lab operates in the healthcare diagnostics sector, specializing in a broad spectrum of medical testing services across multiple regions. The company stands out by offering a dual focus on advanced imaging and comprehensive laboratory diagnostics, thereby delivering integrated diagnostic solutions. Star Imaging & Path Lab caters to a diverse clientele, including individual patients and various healthcare institutions, establishing itself as a key player in providing reliable and accessible diagnostic services. Their commitment to offering end-to-end diagnostic support reinforces their position in the rapidly evolving healthcare landscape.
IPO Structure and Funding Details
| Total Funds Raised | ₹69.47 crores |
|---|---|
| Fresh Issue Component | ₹55.67 crores |
| Offer for Sale Component | ₹13.80 crores |
The total issue size of the Star Imaging & Path Lab IPO is ₹69.47 crores. This includes a fresh issue component of ₹55.67 crores, which represents new shares being issued by the company. Additionally, there is an Offer for Sale (OFS) component amounting to ₹13.80 crores, where existing shareholders will sell their shares. The fresh issue component is crucial as the proceeds from this part directly flow into the company, earmarked for specific growth initiatives and operational enhancements.
Proposed Utilization of IPO Capital
The capital raised through the fresh issue component of the IPO is strategically allocated to bolster Star Imaging & Path Lab’s operational capabilities and facilitate its expansion plans. The primary objectives for utilizing these funds are as follows:
| Objective | Amount (INR Crores) | Allocation % (of Fresh Issue) |
|---|---|---|
| To meet working capital requirements | 25.00 | 44.91% |
| Repayment/prepayment of certain borrowings | 12.00 | 21.55% |
| Funding the capital expenditure towards purchase of refurbished medical equipment in running facilities | 5.14 | 9.23% |
| General corporate purposes | 13.53 | 24.30% |
These allocations are designed to strengthen the company’s financial position, reduce its debt burden, enhance its diagnostic infrastructure, and provide flexibility for general business operations, ultimately contributing to sustainable growth in the competitive healthcare diagnostics market.
Competitive Advantages of Star Imaging & Path Lab
Star Imaging & Path Lab boasts several inherent strengths that position it favorably within the diagnostic healthcare industry:
- Integrated Diagnostic Solutions: The company offers a comprehensive suite of diagnostic services under one roof, including pathology, radiology, cardiology, and neurology. This integrated approach provides convenience and a holistic diagnostic experience for patients and healthcare providers.
- Diversified Revenue Streams: Operating across B2C (Business-to-Consumer), B2B (Business-to-Business), and B2G (Business-to-Government) segments, Star Imaging ensures a broad revenue base and extensive market reach, reducing reliance on a single market segment.
- Robust Network and Strategic Expansion: With a strong network of diagnostic centers and a strategic approach to expansion, the company ensures widespread accessibility to its diagnostic services, catering to a larger population base.
- Experienced Management Team: The leadership team brings a strong track record and extensive experience in the diagnostic healthcare industry, providing strategic direction and operational expertise critical for sustained growth.
- Technological Advancement and PPP Engagement: Continuous investment in advanced diagnostic technology coupled with strategic Public-Private Partnership (PPP) engagements drives significant operational efficiencies and enhances service delivery capabilities.
Potential Considerations and Risk Factors
While Star Imaging & Path Lab presents a compelling investment opportunity, potential investors should also be aware of certain risk factors that could influence the company’s performance:
- Pending Legal Proceedings: Outstanding legal proceedings involving the company, its directors, and promoters could potentially impact cash flows, reputation, and overall operations.
- Geographic Concentration: A high reliance on Delhi and Uttar Pradesh markets makes the business vulnerable to regional disruptions, regulatory changes, or economic downturns specific to these areas.
- Revenue Concentration: A significant portion of revenue is concentrated in pathology and radiology services, increasing the company’s exposure to sector-specific downturns or competitive pressures in these segments.
- Reliance on Third-Party Vendors and Institutional Customers: The business relies on third-party vendors for certain services and a significant portion of its revenue comes from institutional customers without long-term contracts, which could introduce operational and revenue instability.
- Operational and Market Challenges: Recent negative cash flows, intense competition in the diagnostics sector, and potential loss of leased premises could adversely affect the company’s financial health and operational continuity.
Latest Subscription Data Overview
Subscription statistics provide an insight into the investor interest for Star Imaging & Path Lab IPO, based on the latest available information as of 5:00 PM on August 12, 2025:
| Investor Category | Shares Reserved (Lakhs) | Shares Applied (Lakhs) | Subscription (Times) |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | 8.71 | 111.88 | 12.85 |
| Non-Institutional Investors (NII) | 6.57 | 28.75 | 4.38 |
| Retail Individual Investors (RII) | 15.28 | 35.38 | 2.32 |
| Employees | 0.52 | 0.16 | 0.31 |
| Total | 31.08 | 176.17 | 5.67 |
The subscription figures indicate varying levels of interest across different investor categories. Qualified Institutional Buyers have shown robust demand, reflecting strong institutional confidence in the company. Retail and Non-Institutional Investors have also participated, though at a comparatively lower rate. The employee portion received a modest subscription. These figures are dynamic and reflect the market’s response to the IPO during its subscription period.
*Subscription data is based on information from official exchanges and is considered the most reliable indicator of investor interest. Unofficial GMP (Grey Market Premium) figures may vary and are not reflective of the actual market performance.
How to Participate in the IPO
Investors keen on participating in the Star Imaging & Path Lab IPO can do so seamlessly through the official Dhan Kirti IPO platform. Ensure to complete your application before the subscription window closes on August 12, 2025. This is an opportunity to potentially invest in a growing healthcare diagnostics company.
To apply for this IPO and explore other investment opportunities, visit the official Dhan Kirti IPO platform.
